FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy

An FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against recommending approval of a novel strategy for switching breast cancer therapy. While panel members expressed interest in the approach, they ultimately concluded that the available evidence was insufficient to support regulatory approval. The negative vote signals a significant setback for the proposed treatment-switching strategy, though it does not constitute a final FDA decision. This outcome highlights the high evidentiary bar required for novel therapeutic strategies in breast cancer, even when the underlying concept is scientifically appealing.